TargetBeta
IFNAR2
interferon alpha and beta receptor subunit 2 · also IFNABR · Interferon receptors
3 programs in company-led studies act on IFNAR2, from 3 companies: 0 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| peginterferon alfa-2brule | Merck | phase 4 | 562 running | IFNAR1 | ChEMBL |
| peginterferon alfa-2arule | Hoffmann-La Roche | phase 4 | 1001 running | IFNAR1 | ChEMBL |
| Interferon beta-1arule | Biogen | phase 4 | 600 running | IFNA1, IFNAR1 | ChEMBL |
Conditions their studies are in
- Hepatitis B, Chronic, 2 programs
- Hepatitis C, 2 programs
- Hepatitis C, Chronic, 2 programs
- Colitis, Ulcerative, 1 program
- COVID-19, 1 program
- Hepatitis B, 1 program
- Hepatitis D, Chronic, 1 program
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 1 program
- Melanoma, 1 program
- Multiple Sclerosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 30, 2027peginterferon alfa-2a · Hoffmann-La Roche · phase 4 · NCT07389044
- May 31, 2029peginterferon alfa-2b · Merck · phase 4 · NCT06707922
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.